| Name | Title | Contact Details |
|---|
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
NY CREATES is a world leading R&D, innovation hub and commercialization facilitator that works with researchers in industry, academia and national labs to leverage the state of the art infrastructure in upstate New York and to partner with NY CREATES’ ...
Hero was founded to be the world`s most people-focused healthcare company by creating frictionless solutions to the most challenging problems facing patients and caregivers.
AbboMax is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Premise Corporation is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.